Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
About Xenetic Biosciences Inc.
Xenetic Biosciences Inc. (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company dedicated to advancing innovative immuno-oncology technologies and next-generation biologic therapeutics. With a focus on addressing hard-to-treat cancers and other severe medical conditions, Xenetic leverages its proprietary platforms to develop transformative therapies that improve patient outcomes.
Core Technologies
The company's flagship technology, the DNase-based oncology platform, is designed to target neutrophil extracellular traps (NETs), which are implicated in cancer progression, metastasis, and resistance to existing therapies. By reducing NETs burden in the tumor microenvironment, Xenetic's DNase platform enhances the efficacy of immunotherapies, adoptive cell therapies, and chemotherapies. This technology is being developed as an adjunctive treatment for pancreatic carcinoma, colorectal cancer, and other locally advanced or metastatic solid tumors.
Another key innovation is the PolyXen™ platform, which improves the pharmacological properties of biologic drugs, including extended half-life and reduced immunogenicity. This platform is being utilized in collaborations with global pharmaceutical companies to develop next-generation biologics, such as polysialylated blood coagulation factors.
Pipeline and Partnerships
Xenetic's pipeline includes investigational therapies targeting significant unmet needs in oncology. The company is advancing its systemic DNase program into clinical trials, focusing on its potential as an adjunctive therapy in combination with chemotherapy and immune checkpoint inhibitors. Preclinical studies have demonstrated encouraging results, including enhanced tumor suppression, improved T-cell activation, and prolonged survival in animal models.
Collaborations play a pivotal role in Xenetic's strategy. The company has established partnerships with institutions such as the University of Virginia and PeriNess Ltd., leveraging their expertise to accelerate preclinical and clinical development. Additionally, Xenetic's sublicense agreement with Takeda Pharmaceuticals for the PolyXen platform generates royalty revenues, supporting its broader research and development efforts.
Market Position and Competitive Edge
Operating within the highly competitive oncology sector, Xenetic differentiates itself through its focus on NET-targeting therapies and its ability to enhance existing treatment paradigms. By addressing the immunosuppressive tumor microenvironment and improving the efficacy of established therapies, the DNase platform holds the potential to transform treatment outcomes for patients with aggressive and resistant cancers.
The company's emphasis on collaboration, coupled with its proprietary technologies, positions it as a key innovator in the field of immune-oncology. Its strategic focus on hard-to-treat cancers underscores its commitment to addressing significant unmet medical needs.
Conclusion
With a robust pipeline, cutting-edge technologies, and strategic partnerships, Xenetic Biosciences Inc. is at the forefront of developing novel therapies that aim to redefine cancer treatment. By targeting critical mechanisms like NETs and leveraging its expertise in biologics, the company continues to make strides toward delivering impactful solutions for patients and healthcare providers.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) will participate in a Virtual Investor Innovation in Oncology Event on June 9, 2022, at 11:00 AM ET. The event features a roundtable with CEO Jeffrey Eisenberg, Chief Scientific Officer Curtis Lockshin, and oncology expert Allan Tsung, MD. They will discuss Xenetic's DNase-based oncology platform, focusing on how it targets Neutrophil Extracellular Traps (NETs) in cancer treatment. A live video webcast will be available on the Company's website, and questions from the audience will be addressed during the session.
Xenetic Biosciences (NASDAQ: XBIO), a biopharmaceutical company focused on immune-oncology technologies, will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 4:00 PM ET. CEO Jeffrey F. Eisenberg will deliver the presentation in Miami, FL, and virtually. The management team will also be available for one-on-one meetings with investors. A live video webcast will be accessible on the Company's website and archived for 90 days. Xenetic is advancing therapies targeting Neutrophil Extracellular Traps and developing CAR T platform technology.
Xenetic Biosciences (NASDAQ: XBIO) reported its first quarter 2022 financial results, highlighting a net loss of approximately $1.6 million and cash reserves of $16.2 million. The company has completed an exclusive licensing agreement with CLS Therapeutics for a DNase-based oncology platform aimed at enhancing cancer treatment outcomes. The focus is on advancing this platform for Phase 1 clinical development targeting locally advanced or metastatic solid tumors, with an IND filing anticipated by the end of 2023.
Xenetic Biosciences (NASDAQ: XBIO) has announced a transaction with CLS Therapeutics to develop a DNase-based oncology platform, which aims to enhance the efficacy of existing therapies for solid tumors. This includes an exclusive license for DNases in cancer treatment, entailing an upfront payment of $500,000, issuance of shares, and future milestone payments potentially reaching $13 million. The company plans to conduct a Phase 1 clinical study targeting locally advanced or metastatic cancers. The platform seeks to address issues related to Neutrophil Extracellular Traps (NETs), which may hinder cancer treatment outcomes.
Xenetic Biosciences (NASDAQ: XBIO) reported a net loss of $5.6 million for the year ended December 31, 2021, with research and development expenses rising to $3.2 million. The company ended the year with cash reserves of approximately $18.2 million and working capital of about $17.3 million, up from $11.4 million in 2020. Their XCART platform is advancing toward IND-enabling studies, while royalty payments from the PolyXen technology reached $1.2 million, a 166% increase from the previous year. The XCART program targets a potential global market of over $7 billion annually.
Xenetic Biosciences (NASDAQ: XBIO) is advancing its XCART platform towards IND-enabling studies, backed by a strengthened cash position from a recent $12.5 million private placement. The company reported a net loss of $1.4 million for Q3 2021, with R&D expenses rising by 36.1% to $0.8 million. Additionally, royalty streams have grown through its license agreement with PolyXen®, bringing in approximately $0.3 million in royalties. With working capital at $19.5 million, Xenetic is positioned to pursue its innovative cancer therapies effectively.
Xenetic Biosciences (NASDAQ: XBIO) announced a Notice of Allowance from the USPTO for its patent application covering its XCART personalized CAR T therapy. This platform targets tumor-specific neoantigens and aims to improve cancer treatment effectiveness. CEO Jeffrey Eisenberg highlighted this as a significant milestone for the XCART program, which is currently in pre-clinical development for Non-Hodgkin lymphoma. The resulting U.S. patent is expected to expire in 2038, enhancing the company's intellectual property portfolio.
Xenetic Biosciences (NASDAQ: XBIO) has announced that CEO Jeffrey F. Eisenberg will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will focus on the Company's personalized CAR T platform technology, XCART™, designed to target patient-specific tumor neoantigens. A video webcast of the presentation will be available on-demand starting September 13 at 7:00 AM ET, with a replay accessible for 90 days. The Company is also leveraging its PolyXen® platform for drug delivery improvements.
Xenetic Biosciences (NASDAQ: XBIO) reported a net loss of approximately $1.1 million for Q2 2021, with R&D expenses increasing 70.4% to $0.5 million due to advancements in its XCART platform. The company strengthened its position through a $12.5 million private placement and saw royalty growth from its PolyXen technology, totaling about $0.3 million in royalties generated from Takeda's sublicensee. The company is progressing towards IND-enabling studies in the U.S., aiming to address a significant market opportunity in oncology.
Xenetic Biosciences (NASDAQ: XBIO) announced the closure of a private placement, raising approximately $12.5 million by issuing 4,629,630 shares at $2.70 each. The offering included warrants that could generate an additional $15.3 million if fully exercised. Proceeds will be used for general working capital. The shares were sold under a private placement exemption and the company plans to register them within 30 days. Xenetic focuses on advancing its XCART technology for cancer treatment and leveraging its PolyXen drug delivery platform.